Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon’s Fibroblasts

The anti-fibrotic properties of ranibizumab have been well documented. As an antagonist to vascular endothelial growth factor (VEGF), ranibizumab works by binding and neutralizing all active VEGF-A, thus limiting progressive cell growth and proliferation. Ranibizumab application in ocular diseases h...

Full description

Bibliographic Details
Main Authors: Siti Munirah Md Noh, Siti Hamimah Sheikh Abdul Kadir, Sushil Vasudevan
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Biomolecules
Subjects:
Online Access:https://www.mdpi.com/2218-273X/9/6/243
id doaj-d417a70bf4064b368b615ea10287e921
record_format Article
spelling doaj-d417a70bf4064b368b615ea10287e9212020-11-25T01:40:28ZengMDPI AGBiomolecules2218-273X2019-06-019624310.3390/biom9060243biom9060243Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon’s FibroblastsSiti Munirah Md Noh0Siti Hamimah Sheikh Abdul Kadir1Sushil Vasudevan2Faculty of Medicine, Universiti Teknologi MARA (UiTM), Cawangan Sungai Buloh, Selangor 47000, MalaysiaFaculty of Medicine, Universiti Teknologi MARA (UiTM), Cawangan Sungai Buloh, Selangor 47000, MalaysiaFaculty of Medicine, Universiti Teknologi MARA (UiTM), Cawangan Sungai Buloh, Selangor 47000, MalaysiaThe anti-fibrotic properties of ranibizumab have been well documented. As an antagonist to vascular endothelial growth factor (VEGF), ranibizumab works by binding and neutralizing all active VEGF-A, thus limiting progressive cell growth and proliferation. Ranibizumab application in ocular diseases has shown remarkable desired effects; however, to date, its antifibrotic mechanism is not well understood. In this study, we identified metabolic changes in ranibizumab-treated human Tenon&#8217;s fibroblasts (HTFs). Cultured HTFs were treated for 48 h with 0.5 mg/mL of ranibizumab and 0.5 mg/mL control IgG antibody which serves as a negative control. Samples from each group were injected into Agilent 6520 Q-TOF liquid chromatography/mass spectrometer (LC/MS) system to establish the metabolite expression in both ranibizumab treated cells and control group. Data obtained was analyzed using Agilent Mass Hunter Qualitative Analysis software to identify the most regulated metabolite following ranibizumab treatment. At <i>p</i>-value &lt; 0.01 with the cut off value of two-fold change, 31 identified metabolites were found to be significantly upregulated in ranibizumab-treated group, with six of the mostly upregulated having insignificant role in fibroblast cell cycle and wound healing regulations. Meanwhile, 121 identified metabolites that were downregulated, and seven of the mostly downregulated are significantly involved in cell cycle and proliferation. Our findings suggest that ranibizumab abrogates the tissue scarring and wound healing process by regulating the expression of metabolites associated with fibrotic activity. In particular, we found that vitamin Bs are important in maintaining normal folate cycle, nucleotide synthesis, and homocysteine and spermidine metabolism. This study provides an insight into ranibizumab&#8217;s mechanism of action in HTFs from the perspective of metabolomics.https://www.mdpi.com/2218-273X/9/6/243anti-VEGFranibizumabtrabeculectomy
collection DOAJ
language English
format Article
sources DOAJ
author Siti Munirah Md Noh
Siti Hamimah Sheikh Abdul Kadir
Sushil Vasudevan
spellingShingle Siti Munirah Md Noh
Siti Hamimah Sheikh Abdul Kadir
Sushil Vasudevan
Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon’s Fibroblasts
Biomolecules
anti-VEGF
ranibizumab
trabeculectomy
author_facet Siti Munirah Md Noh
Siti Hamimah Sheikh Abdul Kadir
Sushil Vasudevan
author_sort Siti Munirah Md Noh
title Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon’s Fibroblasts
title_short Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon’s Fibroblasts
title_full Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon’s Fibroblasts
title_fullStr Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon’s Fibroblasts
title_full_unstemmed Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon’s Fibroblasts
title_sort important metabolites in maintaining folate cycle, homocysteine, and polyamine metabolism associated with ranibizumab treatment in cultured human tenon’s fibroblasts
publisher MDPI AG
series Biomolecules
issn 2218-273X
publishDate 2019-06-01
description The anti-fibrotic properties of ranibizumab have been well documented. As an antagonist to vascular endothelial growth factor (VEGF), ranibizumab works by binding and neutralizing all active VEGF-A, thus limiting progressive cell growth and proliferation. Ranibizumab application in ocular diseases has shown remarkable desired effects; however, to date, its antifibrotic mechanism is not well understood. In this study, we identified metabolic changes in ranibizumab-treated human Tenon&#8217;s fibroblasts (HTFs). Cultured HTFs were treated for 48 h with 0.5 mg/mL of ranibizumab and 0.5 mg/mL control IgG antibody which serves as a negative control. Samples from each group were injected into Agilent 6520 Q-TOF liquid chromatography/mass spectrometer (LC/MS) system to establish the metabolite expression in both ranibizumab treated cells and control group. Data obtained was analyzed using Agilent Mass Hunter Qualitative Analysis software to identify the most regulated metabolite following ranibizumab treatment. At <i>p</i>-value &lt; 0.01 with the cut off value of two-fold change, 31 identified metabolites were found to be significantly upregulated in ranibizumab-treated group, with six of the mostly upregulated having insignificant role in fibroblast cell cycle and wound healing regulations. Meanwhile, 121 identified metabolites that were downregulated, and seven of the mostly downregulated are significantly involved in cell cycle and proliferation. Our findings suggest that ranibizumab abrogates the tissue scarring and wound healing process by regulating the expression of metabolites associated with fibrotic activity. In particular, we found that vitamin Bs are important in maintaining normal folate cycle, nucleotide synthesis, and homocysteine and spermidine metabolism. This study provides an insight into ranibizumab&#8217;s mechanism of action in HTFs from the perspective of metabolomics.
topic anti-VEGF
ranibizumab
trabeculectomy
url https://www.mdpi.com/2218-273X/9/6/243
work_keys_str_mv AT sitimunirahmdnoh importantmetabolitesinmaintainingfolatecyclehomocysteineandpolyaminemetabolismassociatedwithranibizumabtreatmentinculturedhumantenonsfibroblasts
AT sitihamimahsheikhabdulkadir importantmetabolitesinmaintainingfolatecyclehomocysteineandpolyaminemetabolismassociatedwithranibizumabtreatmentinculturedhumantenonsfibroblasts
AT sushilvasudevan importantmetabolitesinmaintainingfolatecyclehomocysteineandpolyaminemetabolismassociatedwithranibizumabtreatmentinculturedhumantenonsfibroblasts
_version_ 1725045512568045568